慢性肾病患者大型肾脏肿块的99mTc-MIBI SPECT/CT评估
本文报告一例84岁慢性肾病患者,发现11.2 cm肾脏肿块,CT或MRI难以可靠区分良性/惰性肾肿块与侵袭性肿瘤,肾肿块活检有并发症风险且10%至20%结果无法诊断。99mTc-MIBI SPECT/CT结果使患者避免了根治性肾切除术。
要点
- CT或MRI无法可靠区分良性/惰性肾肿块与侵袭性肿瘤。
- 肾肿块活检有并发症风险,10%至20%结果无法诊断。
- 99mTc-MIBI SPECT/CT可准确区分良性肾嗜酸细胞瘤及混合嗜酸细胞/嫌色细胞肿瘤与其他侵袭性肾肿瘤类型。
核心结论
- 99mTc-MIBI SPECT/CT结果使该84岁慢性肾病伴11.2 cm肾脏肿块患者避免了根治性肾切除术。
研究设计与样本
- 本文为病例报告,报告一例84岁慢性肾病伴11.2 cm肾脏肿块男性患者。
主要发现
- 患者为84岁男性,患有慢性肾病,肾脏肿块大小为11.2 cm。
- 99mTc-MIBI SPECT/CT结果使患者避免了根治性肾切除术。
关键数值与推荐
- CT或MRI无法可靠区分良性/惰性肾肿块与侵袭性肿瘤组织学类型。
- 肾肿块活检有并发症风险,无法诊断率为10%至20%。
- 99mTc-MIBI SPECT/CT已被证明可准确区分良性肾嗜酸细胞瘤及混合嗜酸细胞/嫌色细胞肿瘤与其他更具侵袭性的肾肿瘤类型。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The differentiation of benign and indolent renal masses from aggressive tumor histologies cannot be reliably performed by CT or MRI. Additionally, renal mass biopsy risks complications and has a nondiagnostic rate of 10% to 20%. Tc-MIBI SPECT/CT has been shown to allow for the accurate differentiation of benign renal oncocytomas and hybrid oncocytic/chormophobe tumors from other more aggressive renal tumor types. We present the case of an 84-year-old man with chronic kidney disease and an 11.2-cm renal mass. Results of his Tc-MIBI SPECT/CT allowed avoidance of a radical nephrectomy.
引用
- Rowe SP, Gorin MA, Javadi MS, et al. Evaluation of a Large Renal Mass Using 99mTc-MIBI SPECT/CT in a Patient With Chronic Kidney Disease. Clin Nucl Med. 2017. PMID: 28072625. doi:10.1097/RLU.0000000000001533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。